Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anna Arnal-Estapé is active.

Publication


Featured researches published by Anna Arnal-Estapé.


Journal of Clinical Investigation | 2012

Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells

Toni Celià-Terrassa; Óscar Meca-Cortés; Francesca Mateo; Alexia Martínez de Paz; Nuria Rubio; Anna Arnal-Estapé; Brian Ell; Raquel Bermudo; Alba Díaz; Marta Guerra-Rebollo; Juan José Lozano; Conchi Estarás; Catalina Ulloa; Daniel ρlvarez-Simón; Jordi Milà; Ramón Vilella; Rosanna Paciucci; Marian A. Martínez-Balbás; Antonio García de Herreros; Roger R. Gomis; Yibin Kang; Jerónimo Blanco; Pedro L. Fernández; Timothy M. Thomson

Malignant progression in cancer requires populations of tumor-initiating cells (TICs) endowed with unlimited self renewal, survival under stress, and establishment of distant metastases. Additionally, the acquisition of invasive properties driven by epithelial-mesenchymal transition (EMT) is critical for the evolution of neoplastic cells into fully metastatic populations. Here, we characterize 2 human cellular models derived from prostate and bladder cancer cell lines to better understand the relationship between TIC and EMT programs in local invasiveness and distant metastasis. The model tumor subpopulations that expressed a strong epithelial gene program were enriched in highly metastatic TICs, while a second subpopulation with stable mesenchymal traits was impoverished in TICs. Constitutive overexpression of the transcription factor Snai1 in the epithelial/TIC-enriched populations engaged a mesenchymal gene program and suppressed their self renewal and metastatic phenotypes. Conversely, knockdown of EMT factors in the mesenchymal-like prostate cancer cell subpopulation caused a gain in epithelial features and properties of TICs. Both tumor cell subpopulations cooperated so that the nonmetastatic mesenchymal-like prostate cancer subpopulation enhanced the in vitro invasiveness of the metastatic epithelial subpopulation and, in vivo, promoted the escape of the latter from primary implantation sites and accelerated their metastatic colonization. Our models provide new insights into how dynamic interactions among epithelial, self-renewal, and mesenchymal gene programs determine the plasticity of epithelial TICs.


Journal of Biological Chemistry | 2012

Identification of NOG as a specific breast cancer bone metastasis-supporting gene.

Maria Tarragona; Milica Pavlovic; Anna Arnal-Estapé; Jelena Urosevic; Mónica Morales; Marc Guiu; Evarist Planet; Eva González-Suárez; Roger R. Gomis

Background: NOG gene is required for accumulation of mature osteoclasts and proper skeletal development. Results: NOG mediates breast cancer metastatic bone colonization by osteoclast differentiation and self-renewal metastatic properties. Conclusion: Expression of NOG in breast metastatic cancer cells provides them with bone colonization capabilities. Significance: The interplay of bone microenvironment and cancer cell autonomous functions define the selection of genes that lead to bone metastasis development. Metastasis requires numerous biological functions that jointly provide tumor cells from a primary site to seed and colonize a distant organ. Some of these activities are selected for in the primary site, whereas others are acquired at the metastatic niche. We provide molecular evidence showing that the BMP inhibitor, NOG, provides metastatic breast cancer cells with the ability to colonize the bone. NOG expression is acquired during the late events of metastasis, once cells have departed from the primary site, because it is not enriched in primary tumors with high risk of bone relapse. On the contrary, breast cancer bone metastatic lesions do select for high levels of NOG expression when compared with metastasis to the lung, liver, and brain. Pivotal to the bone colonization functions is the contribution of NOG to metastatic autonomous and nonautonomous cell functions. Using genetic approaches, we show that when NOG is expressed in human breast cancer cells, it facilitates bone colonization by fostering osteoclast differentiation and bone degradation and also contributes to metastatic lesions reinitiation. These findings reveal how aggressive cancer cell autonomous and nonautonomous functions can be mechanistically coupled to greater bone metastatic potential.


Cancer Research | 2010

HER2 Silences Tumor Suppression in Breast Cancer Cells by Switching Expression of C/EBPβ Isoforms

Anna Arnal-Estapé; Maria Tarragona; Monica Morales; Marc Guiu; Cristina Nadal; Joan Massagué; Roger R. Gomis

Tumor progression requires ablation of suppressor functions mediated by transforming growth factor β (TGFβ) signaling and by oncogene-induced senescence (OIS), but how these functions are canceled in specific subtypes of breast cancer remains unknown. In this study, we show that HER2-overexpressing breast cancer cells avert TGFβ- and OIS-mediated tumor suppression by switching expression of 2 functionally distinct isoforms of the transcription factor C/EBPβ, which has been implicated previously in breast cancer development. HER2 signaling activates the translational regulatory factor CUGBP1, which favors the production of the transcriptionally inhibitory isoform LIP over that of the active isoform LAP. LIP overexpression prevents the assembly of LAP/Smad transcriptional repressor complexes on the MYC promoter in response to TGFβ, and interferes with activation of OIS responses. Treatment of HER2-transformed mammary epithelial cells with the HER2 antibody trastuzumab reduces LIP levels, restoring these suppressor responses. Our findings reveal a novel mechanism through which HER2 silences tumor suppression in a concerted manner, contributing to the potency of this oncogene in breast cancer.


Journal of the National Cancer Institute | 2015

Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis

Milica Pavlovic; Anna Arnal-Estapé; Federico Rojo; Anna Bellmunt; Maria Tarragona; Marc Guiu; Evarist Planet; Xabier García-Albéniz; Mónica Morales; Jelena Urosevic; Sylwia Gawrzak; Ana Rovira; Aleix Prat; Lara Nonell; Ana Lluch; Joël Jean-Mairet; Robert E. Coleman; Joan Albanell; Roger R. Gomis

Background: There are currently no biomarkers for early breast cancer patient populations at risk of bone metastasis. Identification of mediators of bone metastasis could be of clinical interest. Methods: A de novo unbiased screening approach based on selection of highly bone metastatic breast cancer cells in vivo was used to determine copy number aberrations (CNAs) associated with bone metastasis. The CNAs associated with bone metastasis were examined in independent primary breast cancer datasets with annotated clinical follow-up. The MAF gene encoded within the CNA associated with bone metastasis was subjected to gain and loss of function validation in breast cancer cells (MCF7, T47D, ZR-75, and 4T1), its downstream mechanism validated, and tested in clinical samples. A multivariable Cox cause-specific hazard model with competing events (death) was used to test the association between 16q23 or MAF and bone metastasis. All statistical tests were two-sided. Results: 16q23 gain CNA encoding the transcription factor MAF mediates breast cancer bone metastasis through the control of PTHrP. 16q23 gain (hazard ratio (HR) for bone metastasis = 14.5, 95% confidence interval (CI) = 6.4 to 32.9, P < .001) as well as MAF overexpression (HR for bone metastasis = 2.5, 95% CI = 1.7 to 3.8, P < .001) in primary breast tumors were specifically associated with risk of metastasis to bone but not to other organs. Conclusions: These results suggest that MAF is a mediator of breast cancer bone metastasis. 16q23 gain or MAF protein overexpression in tumors may help to select patients at risk of bone relapse.


Cancer Discovery | 2015

Sweets for a Bitter End: Lung Cancer Cell–Surface Protein Glycosylation Mediates Metastatic Colonization

Anna Arnal-Estapé; Don X. Nguyen

Glycosylation is one of the most predominant forms of cell-surface protein modifications, yet its deregulation in cancer and contribution to tumor microenvironment interactions remain poorly understood. In this issue of Cancer Discovery, Reticker-Flynn and Bhatia characterize an enzymatic switch in lung cancer cells that triggers aberrant surface protein glycosylation patterns, adhesion to lectins on the surface of inflammatory cells, and subsequent metastatic colonization of the liver.


Nature Cell Biology | 2018

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer

Sylwia Gawrzak; Lorenzo Rinaldi; Sara Gregorio; Enrique J. Arenas; Fernando Salvador; Jelena Urosevic; Cristina Figueras-Puig; Federico Rojo; Ivan del Barco Barrantes; Juan Miguel Cejalvo; Marta Palafox; Marc Guiu; Antonio Berenguer-Llergo; Aikaterini Symeonidi; Anna Bellmunt; Daniela Kalafatovic; Anna Arnal-Estapé; Esther Fernández; Barbara Müllauer; Rianne Groeneveld; Konstantin Slobodnyuk; Camille Stephan-Otto Attolini; Cristina Saura; J. Arribas; Javier Cortes; Ana Rovira; Montse Muñoz; Ana Lluch; Violeta Serra; Joan Albanell

For many patients with breast cancer, symptomatic bone metastases appear after years of latency. How micrometastatic lesions remain dormant and undetectable before initiating colonization is unclear. Here, we describe a mechanism involved in bone metastatic latency of oestrogen receptor-positive (ER+) breast cancer. Using an in vivo genome-wide short hairpin RNA screening, we identified the kinase MSK1 as an important regulator of metastatic dormancy in breast cancer. In patients with ER+ breast cancer, low MSK1 expression associates with early metastasis. We show that MSK1 downregulation impairs the differentiation of breast cancer cells, increasing their bone homing and growth capacities. MSK1 controls the expression of genes required for luminal cell differentiation, including the GATA3 and FOXA1 transcription factors, by modulating their promoter chromatin status. Our results indicate that MSK1 prevents metastatic progression of ER+ breast cancer, suggesting that stratifying patients with breast cancer as high or low risk for early relapse based on MSK1 expression could improve prognosis.Gawrzak et al. show that MSK1 regulates bone metastatic dormancy of ER+ breast cancer. MSK1 affects histone modifications at luminal transcription factor promoters to prevent cell differentiation and bone homing.


The Breast | 2011

Tumor-stroma interactions a trademark for metastasis

Monica Morales; Evarist Planet; Anna Arnal-Estapé; Milica Pavlovic; Maria Tarragona; Roger R. Gomis

AIMS We aimed to unravel genes that are significantly associated with metastasis in order to identify functions that support disseminated disease. METHODS AND RESULTS We identify genes associated with metastasis and verify its clinical correlations using publicly available primary tumor expression profile data sets. We used facilities in R and Bioconductor (GSEA). Specific data structures and functions were imported. Our results show that genes associated with metastasis in primary tumor enriched for pathways associated with immune infiltration or cytokine-cytokine receptor interaction. As an example, we focus on the enrichment of TGFBR2 and TGF|X A set of communication tools capital for tumor-stroma interactions that define metastasis to the lung and support bone colonization. CONCLUSIONS We showed that tumor-stroma communication through cytokine-cytokine receptor interaction pathway is selected in primary tumors with high risk of relapse. High levels of these factors support systemic instigation of the far metastatic nest as well as local metastatic-specific functions that provide solid ground for metastatic development.


Cancer Research | 2017

Extracellular matrix receptor expression in subtypes of lung adenocarcinoma potentiates outgrowth of micrometastases.

Laura E. Stevens; William K.C. Cheung; Sally J. Adua; Anna Arnal-Estapé; Minghui Zhao; Zongzhi Liu; Kelly Brewer; Roy S. Herbst; Don X. Nguyen

Mechanisms underlying the propensity of latent lung adenocarcinoma (LUAD) to relapse are poorly understood. In this study, we show how differential expression of a network of extracellular matrix (ECM) molecules and their interacting proteins contributes to risk of relapse in distinct LUAD subtypes. Overexpression of the hyaluronan receptor HMMR in primary LUAD was associated with an inflammatory molecular signature and poor prognosis. Attenuating HMMR in LUAD cells diminished their ability to initiate lung tumors and distant metastases. HMMR upregulation was not required for dissemination in vivo, but enhanced ECM-mediated signaling, LUAD cell survival, and micrometastasis expansion in hyaluronan-rich microenvironments in the lung and brain metastatic niches. Our findings reveal an important mechanism by which disseminated cancer cells can coopt the inflammatory ECM to persist, leading to brain metastatic outgrowths. Cancer Res; 77(8); 1905-17. ©2017 AACR.


Nature Cell Biology | 2018

Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer

Sylwia Gawrzak; Lorenzo Rinaldi; Sara Gregorio; Enrique J. Arenas; Fernando Salvador; Jelena Urosevic; Cristina Figueras-Puig; Federico Rojo; Ivan del Barco Barrantes; Juan Miguel Cejalvo; Marta Palafox; Marc Guiu; Antonio Berenguer-Llergo; Aikaterini Symeonidi; Anna Bellmunt; Daniela Kalafatovic; Anna Arnal-Estapé; Esther Fernández; Barbara Müllauer; Rianne Groeneveld; Konstantin Slobodnyuk; Camille Stephan-Otto Attolini; Cristina Saura; Joaquín Arribas; Javier Cortes; Ana Rovira; Montse Muñoz; Ana Lluch; Violeta Serra; Joan Albanell

In the version of this Article originally published, the boxes framing the two plots in Fig. 1g were misaligned from the axes due to a technical error. This has now been corrected in all versions of the Article.


Journal of Visualized Experiments | 2018

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment

Laura E. Stevens; Anna Arnal-Estapé; Don X. Nguyen

Lung cancer is a deadly treatment refractory disease that is biologically heterogeneous. To understand and effectively treat the full clinical spectrum of thoracic malignancies, additional animal models that can recapitulate diverse human lung cancer subtypes and stages are needed. Allograft or xenograft models are versatile and enable the quantification of tumorigenic capacity in vivo, using malignant cells of either murine or human origin. However, previously described methods of lung cancer cell engraftment have been performed in non-physiological sites, such as the flank of mice, due to the inefficiency of orthotopic transplantation of cells into the lungs. In this study, we describe a method to enhance orthotopic lung cancer cell engraftment by pre-conditioning the airways of mice with the fibrosis inducing agent bleomycin. As a proof-of-concept experiment, we applied this approach to engraft tumor cells of the lung adenocarcinoma subtype, obtained from either mouse or human sources, into various strains of mice. We demonstrate that injuring the airways with bleomycin prior to tumor cell injection increases the engraftment of tumor cells from 0-17% to 71-100%. Significantly, this method enhanced lung tumor incidence and subsequent outgrowth using different models and mouse strains. In addition, engrafted lung cancer cells disseminate from the lungs into relevant distant organs. Thus, we provide a protocol that can be used to establish and maintain new orthotopic models of lung cancer with limiting amounts of cells or biospecimen and to quantitatively assess the tumorigenic capacity of lung cancer cells in physiologically relevant settings.

Collaboration


Dive into the Anna Arnal-Estapé's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ana Lluch

University of Valencia

View shared research outputs
Top Co-Authors

Avatar

Ana Rovira

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ali Zahalka

Albert Einstein College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Fumio Nakahara

Albert Einstein College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Maria Maryanovich

Albert Einstein College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge